Rigel drops wAIHA sNDA after FDA feedback; cuts 16% workforce, 30 jobs

RIGEL PHARMACEUTICALS INC

FDA guidance on FORWARD Phase 3 re-analysis leads Rigel to halt sNDA for fostamatinib in wAIHA.
Workforce reduction of 16% (30 positions) primarily in development and admin; completion by Jan 31, 2023.
One-time cash severance charge of ~$1.5M in Q4 2022; expects $7-8M annual savings from 2023.
General counsel Dolly Vance retires effective Oct 11, 2022; remains as employee through Nov 30, 2022.

item 2.05 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dolly A. Vance

general counsel

RIGL · RIGEL PHARMACEUTICALS INC

Effective: 2022-10-11
Filed: October 11, 2022, 7:59 PM ET

On October 11, 2022, Dolly A. Vance provided notice of her retirement from her position as general counsel, executive vice president, corporate affairs, and corporate secretary of Rigel, effective the date of this current report.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dolly A. Vance retired as general counsel at RIGEL PHARMACEUTICALS INC.

Action: retired
Role: general counsel

Exact text from the filing

On October 11, 2022, Dolly A. Vance provided notice of her retirement from her position as general counsel, executive vice president, corporate affairs, and corporate secretary of Rigel, effective the date of this current report.

View on SEC.gov

RIGEL PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-22-107725

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.